Compounds > perfluorobutane
Page last updated: 2024-08-21

perfluorobutane and niacinamide

perfluorobutane has been researched along with niacinamide in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kikuchi, Y; Kudo, T; Maruyama, K; Shiozawa, K; Sumino, Y; Watanabe, M1
Furuichi, Y; Imai, Y; Kamiyama, N; Moriyasu, F; Rognin, N; Saito, K; Sugimoto, K1
Igarashi, Y; Ikehara, T; Kikuchi, Y; Kogame, M; Matsukiyo, Y; Shinohara, M; Shiozawa, K; Sumino, Y; Watanabe, M1

Other Studies

3 other study(ies) available for perfluorobutane and niacinamide

ArticleYear
Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography: a pilot study.
    World journal of gastroenterology, 2012, Oct-28, Volume: 18, Issue:40

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Contrast Media; Disease Progression; Ferric Compounds; Humans; Iron; Liver Neoplasms; Male; Middle Aged; Niacinamide; Oxides; Phenylurea Compounds; Pilot Projects; Predictive Value of Tests; Protein Kinase Inhibitors; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography

2012
Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US.
    Liver international : official journal of the International Association for the Study of the Liver, 2013, Volume: 33, Issue:4

    Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Area Under Curve; Carcinoma, Hepatocellular; Contrast Media; Disease-Free Survival; Female; Ferric Compounds; Humans; Iron; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Oxides; Perfusion Imaging; Phenylurea Compounds; Predictive Value of Tests; Prospective Studies; Protein Kinase Inhibitors; Reproducibility of Results; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography

2013
[Evaluation of Sorafenib for Hepatocellular Carcinoma with Low α-Fetoprotein by Arrival Time Parametric Imaging Using Contrast-Enhanced Ultrasonography with Sonazoid].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:2

    Topics: Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Contrast Media; Female; Ferric Compounds; Humans; Iron; Liver Neoplasms; Male; Middle Aged; Niacinamide; Oxides; Phenylurea Compounds; Sorafenib; Time Factors; Ultrasonography

2016